| Dr Spencer Gorsline, MD | |
|
85 High St, Buffalo, NY 14203-1149 | |
| (716) 630-1000 | |
| Not Available |
| Full Name | Dr Spencer Gorsline |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 14 Years |
| Location | 85 High St, Buffalo, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154648897 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 270616 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Vna Of Western Ny Chha | Williamsville, NY | Home health agency |
| Mercy Hospital Of Buffalo | Buffalo, NY | Hospital |
| Brooks-tlc Hospital System, Inc | Dunkirk, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Seneca Nation Of Indians | 8123920592 | 18 |
| Mercy Hospital Of Buffalo | 8729991666 | 165 |
News Archive
LUMEDX Corporation, a leading provider of vendor-neutral, integrated medical imaging and information systems, announced today that 50 hospitals now subscribe to its cardiovascular software-as-a-service (SaaS) solution. LUMEDX's SaaS delivery model allows clients to access and utilize software remotely via the web — resulting in faster implementations and lower licensing, maintenance and personnel costs. The service also includes built-in disaster recovery and high-intensity security systems.
Anurag Singh, PhD, assistant professor in the Department of Pharmacology and Experimental Therapeutics at Boston University School of Medicine has been invited to present his recent work on targeted therapeutics for colon cancer at the American Association of Cancer Research Annual Meeting in Chicago, IL.
PharmaMar announced today the start of a phase III study for the anticancer agent PM1183 in patients with platinum-resistant ovarian cancer (PROC). Once study objectives are met, the CORAIL trial (NCT02421588) will be used to support the regulatory filing of PM1183 as treatment for this indication.
Elevated levels of nitrogen dioxide in the air may be associated with a high number of deaths from Covid-19. A new study by Martin Luther University Halle-Wittenberg (MLU) provides concrete data that back this assumption for the first time.
Men with aggressive prostate cancer that has stopped responding to conventional treatment could potentially benefit from a new class of cancer drug designed to overcome drug resistance, a new study suggests.
› Verified 4 days ago
| Entity Name | Seneca Nation Of Indians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023033511 PECOS PAC ID: 8123920592 Enrollment ID: O20040126000146 |
News Archive
LUMEDX Corporation, a leading provider of vendor-neutral, integrated medical imaging and information systems, announced today that 50 hospitals now subscribe to its cardiovascular software-as-a-service (SaaS) solution. LUMEDX's SaaS delivery model allows clients to access and utilize software remotely via the web — resulting in faster implementations and lower licensing, maintenance and personnel costs. The service also includes built-in disaster recovery and high-intensity security systems.
Anurag Singh, PhD, assistant professor in the Department of Pharmacology and Experimental Therapeutics at Boston University School of Medicine has been invited to present his recent work on targeted therapeutics for colon cancer at the American Association of Cancer Research Annual Meeting in Chicago, IL.
PharmaMar announced today the start of a phase III study for the anticancer agent PM1183 in patients with platinum-resistant ovarian cancer (PROC). Once study objectives are met, the CORAIL trial (NCT02421588) will be used to support the regulatory filing of PM1183 as treatment for this indication.
Elevated levels of nitrogen dioxide in the air may be associated with a high number of deaths from Covid-19. A new study by Martin Luther University Halle-Wittenberg (MLU) provides concrete data that back this assumption for the first time.
Men with aggressive prostate cancer that has stopped responding to conventional treatment could potentially benefit from a new class of cancer drug designed to overcome drug resistance, a new study suggests.
› Verified 4 days ago
| Entity Name | Mercy Hospital Of Buffalo |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164464921 PECOS PAC ID: 8729991666 Enrollment ID: O20040702001253 |
News Archive
LUMEDX Corporation, a leading provider of vendor-neutral, integrated medical imaging and information systems, announced today that 50 hospitals now subscribe to its cardiovascular software-as-a-service (SaaS) solution. LUMEDX's SaaS delivery model allows clients to access and utilize software remotely via the web — resulting in faster implementations and lower licensing, maintenance and personnel costs. The service also includes built-in disaster recovery and high-intensity security systems.
Anurag Singh, PhD, assistant professor in the Department of Pharmacology and Experimental Therapeutics at Boston University School of Medicine has been invited to present his recent work on targeted therapeutics for colon cancer at the American Association of Cancer Research Annual Meeting in Chicago, IL.
PharmaMar announced today the start of a phase III study for the anticancer agent PM1183 in patients with platinum-resistant ovarian cancer (PROC). Once study objectives are met, the CORAIL trial (NCT02421588) will be used to support the regulatory filing of PM1183 as treatment for this indication.
Elevated levels of nitrogen dioxide in the air may be associated with a high number of deaths from Covid-19. A new study by Martin Luther University Halle-Wittenberg (MLU) provides concrete data that back this assumption for the first time.
Men with aggressive prostate cancer that has stopped responding to conventional treatment could potentially benefit from a new class of cancer drug designed to overcome drug resistance, a new study suggests.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Spencer Gorsline, MD 425 Essjay Rd Ste 170, Williamsville, NY 14221-8235 Ph: (716) 630-1219 | Dr Spencer Gorsline, MD 85 High St, Buffalo, NY 14203-1149 Ph: (716) 630-1000 |
News Archive
LUMEDX Corporation, a leading provider of vendor-neutral, integrated medical imaging and information systems, announced today that 50 hospitals now subscribe to its cardiovascular software-as-a-service (SaaS) solution. LUMEDX's SaaS delivery model allows clients to access and utilize software remotely via the web — resulting in faster implementations and lower licensing, maintenance and personnel costs. The service also includes built-in disaster recovery and high-intensity security systems.
Anurag Singh, PhD, assistant professor in the Department of Pharmacology and Experimental Therapeutics at Boston University School of Medicine has been invited to present his recent work on targeted therapeutics for colon cancer at the American Association of Cancer Research Annual Meeting in Chicago, IL.
PharmaMar announced today the start of a phase III study for the anticancer agent PM1183 in patients with platinum-resistant ovarian cancer (PROC). Once study objectives are met, the CORAIL trial (NCT02421588) will be used to support the regulatory filing of PM1183 as treatment for this indication.
Elevated levels of nitrogen dioxide in the air may be associated with a high number of deaths from Covid-19. A new study by Martin Luther University Halle-Wittenberg (MLU) provides concrete data that back this assumption for the first time.
Men with aggressive prostate cancer that has stopped responding to conventional treatment could potentially benefit from a new class of cancer drug designed to overcome drug resistance, a new study suggests.
› Verified 4 days ago
Dr. Robinder Bahniwal, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 34 Benwood Avenue, Buffalo, NY 14215 Phone: 716-986-9199 | |
Ashley L Wyant, PA-C Family Medicine Medicare: Medicare Enrolled Practice Location: 1021 Broadway St, Buffalo, NY 14212 Phone: 716-529-2030 | |
Maxiam Dean, Family Medicine Medicare: Medicare Enrolled Practice Location: 3495 Bailey Ave, Buffalo, NY 14215 Phone: 716-834-9200 | |
Douglas Howard Moffat, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 360 Forest Ave, Buffalo, NY 14213 Phone: 716-882-4900 Fax: 416-882-4426 | |
Dr. Michael Henry Kueker, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 40 La Riviere Dr Ste 201, Buffalo, NY 14202 Phone: 716-893-1010 Fax: 716-893-1002 | |
Patricia A Pastore, FNP Family Medicine Medicare: Medicare Enrolled Practice Location: 300 Niagara St, Niagara Family Health Center, Buffalo, NY 14201 Phone: 716-859-4110 Fax: 716-859-4179 | |
Jharna Basak, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 187 Cazenovia St, Buffalo, NY 14210 Phone: 716-823-3462 Fax: 716-823-9397 |